Nature Biotechnology published an Editor's Pick feature on August 3, 2026, highlighting biotechnology firm Excelsior Sciences. Each year, Nature Biotechnology selects and showcases companies that received sizeable early-stage funding during the previous calendar year. Author C. Schmidt prepared the feature for the journal.
Excelsior Sciences is currently developing a closed-loop system engineered for drug discovery. The platform relies on carbon building bloccs to carry out its drug discovery operations.
Research citations
Authors C. Li, A. S. Grillo, and M. D. Burke published a 2015 study referenced in the report, appearing in Accounts of Chemical Research, volume 48, pages 2297 through 2307.
D. J. Blair and co-authors published a second referenced paper in 2022. That study appeared in Nature, volume 604, spanning pages 92 to 97.
Publication details
Nature Biotechnology published the version of record for the report on August 3, 2026, under the digital object identifier https://doi.org/10.1038/s41587-026-03249-3.
Springer Nature provided the content through its SharedIt content-sharing initiative. Excelsior Sciences did not disclose the exact financial figure of the early-stage funding it received in the previous year.
